ArticleBiological trace element research2025
Effect of Arsenic Exposure on AS3MT Protein Levels in Serum of Type 2 Diabetic Patients Compared to Non-diabetics.
Article in Biological trace element research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research explores the impact of arsenic exposure on serum protein profiles in type 2 diabetes patients, with an emphasis on the AS3MT protein as a biomarker. Utilizing Bradford protein assay, SDS-PAGE, HPLC, and mass spectrometry, we quantified and analyzed variations in serum protein levels, focusing on differences between control groups (82.94 ± 8.03 µg/mL) and diabetic patients (96.95 ± 5.02 µg/mL) of high arsenic exposed in areas Kasur and Lahore, Punjab, Pakistan. The study revealed a significant increase in total serum proteins and specifically identified elevated levels of AS3MT in the diabetic group compared to controls. By using 15% gel, proteins were separated, and bands were visible at 42KD. Further investigations using HPLC provided a detailed chromatographic profile of AS3MT, isolating this protein effectively and displaying its heightened abundance through a marked peak within the sample chromatograms. Additionally, intact mass and tryptic digestion profiles analyzed by mass spectrometry (molecular weight of 41,747.79 D) further corroborated the identity and modification of AS3MT in the context of arsenic exposure. ELISA was used for the quantification of AS3MT protein concentration, and a 260% increase was confirmed in the diabetic group exposed to arsenic. These findings suggested that arsenic exposure significantly alters AS3MT protein and serum protein levels in diabetic patients, supporting the hypothesis that AS3MT can serve as a biomarker for arsenic-induced diabetic conditions.
Indexed as
Identifiers
39699707What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.